Compare Charles River Laboratories Intl. Inc (CRL) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Futu Holdings Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Futu Holdings Ltd trades at $113.71 (market cap $15.25B). The key difference: Charles River Laboratories Intl. Inc and Futu Holdings Ltd are close in size by market cap, and Futu Holdings Ltd pays a 2.39% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Futu Holdings Ltd for 34 Days on average.
| CRL | FUTU | |
|---|---|---|
Market Cap | $14.23B | $15.25B |
Volume | 1,176,885 | 812,567 |
Sector | Health | Financials |
52-Week High | $310.77 | $199.04 |
52-Week Low | $149.93 | $89.76 |
Typical Hold Time | 33 Days | 34 Days |
Enterprise Value | $17.06B | $15.59B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
FUTU trades at $113.71, up 3.67% today, with a bearish technical signal but strong fundamentals including a 10.86 P/E ratio and 42.92% net margin. Revenue grew to $22.85B in 2025, and cash flow surged to $31.02B in 2024. Recent news highlights expansion efforts like the Moomoo X partnership and a class action lawsuit deadline.
The outlook is mixed: analysts see a 33.7% upside (Zacks, 2026-09-10), but technicals and legal risks weigh. Investment opportunity lies in valuation and growth; risks include lawsuit uncertainty and competitive pressures. Earnings beat in Q2 2026 supports momentum, but Q1 2026 miss shows volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
